USP9x antibody | knockout validation | Abcam ab180191

This is a knockout-validated antibody summary, based on the publication "USP9X promotes apoptosis in cholangiocarcinoma by modulation expression of KIF1Bβ via deubiquitinating EGLN3", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

USP9x antibody | knockout validation | Abcam ab180191 figure 1
Figure 1. RBE and HUCCT cells parental or stably expressing USP9X knockout and EGLN3 alone or in combination were subjected to analysis by immunoblotting. From [1].
Antibody information

Rabbit monoclonal IgG

Company: Abcam

Antibody: USP9x

Catalog number: ab180191

Summary: Rabbit monoclonal antibody against a synthetic peptide within human USP9x (aa 1-100, Cysteine residue). Reacts with mouse and human. It is predicted to work with rat. Suitable for western blot, immunoprecipitation, immunocytochemistry/immunofluorescence, immunohistochemistry (paraffin), and flow cytometry (intra).

Validation Method

Western blot

Sample

Parental and USP9X-KO RBE and HUCCT cells.

Primary incubation

1:1,500 dilution.

Detection

Enhanced chemiluminescent substrate kit (Yeasen).

References
  1. Chen W, Song J, Liu S, Tang B, Shen L, Zhu J, et al. USP9X promotes apoptosis in cholangiocarcinoma by modulation expression of KIF1Bβ via deubiquitinating EGLN3. J Biomed Sci. 2021;28:44 pubmed publisher